

Presentation

Symptoms: often **nonspecific**; dyspnea, cough, chest pain, hemoptysis & syncope
 Examination: tachypnoea, fever, hypoxia, tachycardia, elevated JVP, loud P2, S3/4 gallop & diaphoresis

Investigation

FBC/liver/renal, D-dimer, PT/APTT/fibrinogen, troponin, BNP/ NT-proBNP, ABG
 ECG: sinus tachycardia, QR in V1, TWI V1-4, RBBB, S1Q3T3
 Radiology: CXR, CT pulmonary angiography, V/Q scan
 Echocardiogram: evidence of RV strain

Risk stratification

Wells' criteria: pre- test probability of PE

0- 2: 3.6% (low)	Clinical signs & sx of DVT	3 points
3- 6: 20.5% (mod)	No alternative dx	3 points
>6: 66.7% high	HR >100	1.5 points
	Immobilisation >3d/surgery in last 4/52	1.5 points
	Haemoptysis	1 point
	Malignancy w active RX in last 6/12 or pall care	1 point

Consider D-dimer in moderate/high risk groups

PESI: predicts 30- day mortality

<65: v low risk	Age	SBP <100mmHg
66- 85: low risk	Sex	RR >30
86- 105: intermediate	Hx Cancer	T <36
106-125: high risk	Hx heart failure	O2 sats <90% RA
>125: v high risk	Chronic lung disease	HR >110
	Altered mental status	

Consider RV function, biomarkers and hemodynamics when deciding management in intermediate/ high risk groups

1. Thrombolysis?

Consider if massive or high-risk sub- massive PE

Otherwise unexplained SBP <90mmHg

No evidence of hemodynamic instability

SBP >90mmHg

2. Anticoagulation

For all patients

Specific treatment

Consider retrievable IVC filter if CI to OAC

Retrieve as soon as OAC restarted

3. Supportive Care

Should not be delayed

Telemetry & Bed Rest

Unprovoked ?

Oxygen as needed to maintain O2 Sats

Appropriate analgesia & education

4. OAC Duration

Unprovoked versus risk factors

1° treatment (3-6/12)

A. Systemic thrombolysis

First line: alteplase 100mg IV over 2h std dose; 2% risk ICH; 6% risk of other major bleed

B. Catheter-directed lysis

If higher bleeding risk ; IR dept

C. IR- thrombectomy

Failed or CI to tPa

D. Surgical embolectomy

Last resort/ CI to tPa; approx. 10% mortality

Initial: SC LWMH

UFH if high risk for requiring tPa
 Commence DOAC first-line if low risk

Discharge: DOAC

Unless renal disease , mod/ severe liver disease or anti-phospholipid syndrome
 LWMH/ Apixaban (Caravaggio) in cancer associated VTE

Telemetry & Bed Rest

If sub-massive PE or evidence of RV strain

Look for underlying cause

Full hx and examination, basic bloods, CXR
 Gender/ age specific tests: FOB, PSA, mammogram, smear
 ± CT TAP, scopes only if above tests suggestive

1° treatment (3-6/12)

Everyone

± 2° treatment (indefinite)

Unprovoked/ chronic risk factors
 Reassess risks and benefits regularly

Risk factors

Transient

MAJOR (within 3/12 of VTE)
 Surgery GA >30mins
 Bedbound >3d with acute illness
 C-section

MINOR (within 2/12 of VTE)
 GA <30mins
 Admission >3d with acute illness
 Oestrogen
 Pregnancy/ PP
 Bedbound at home >3d with illness
 Leg injury with reduced mobility >3d

Chronic (persistent)

Active cancer
 IBD
 AI disorder
 Chronic infections
 Chronic immobility